AUTHOR=Xu Jiqian , Yang Xiaobo , Lv Zheng , Zhou Ting , Liu Hong , Zou Xiaojing , Cao Fengsheng , Zhang Lu , Liu Boyi , Chen Wei , Yu Yuan , Shu Huaqing , Yuan Shiying , Hu Ming , Huang Chaolin , Shang You 

TITLE=Risk Factors for Invasive Aspergillosis in Patients Admitted to the Intensive Care Unit With Coronavirus Disease 2019: A Multicenter Retrospective Study

JOURNAL=Frontiers in Medicine

VOLUME=8

YEAR=2021

URL=https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2021.753659

DOI=10.3389/fmed.2021.753659

ISSN=2296-858X

ABSTRACT=<p><bold>Background:</bold> Invasive pulmonary aspergillosis (IPA) is a life-threatening complication in coronavirus disease 2019 (COVID-19) patients admitted to intensive care units (ICUs), but risk factors for COVID-19-associated IPA (CAPA) have not been fully characterized. The aim of the current study was to identify factors associated with CAPA, and assess long-term mortality.</p><p><bold>Methods:</bold> A retrospective cohort study of adult COVID-19 patients admitted to ICUs from six hospitals was conducted in Hubei, China. CAPA was diagnosed via composite clinical criteria. Demographic information, clinical variables, and 180-day outcomes after the diagnosis of CAPA were analyzed.</p><p><bold>Results:</bold> Of 335 critically ill patients with COVID-19, 78 (23.3%) developed CAPA within a median of 20.5 days (range 13.0–42.0 days) after symptom onset. Compared to those without CAPA, CAPA patients were more likely to have thrombocytopenia (50 vs. 19.5%, <italic>p</italic> &lt; 0.001) and secondary bacterial infection prior to being diagnosed with CAPA (15.4 vs. 6.2%, <italic>p</italic> = 0.013), and to receive vasopressors (37.2 vs. 8.6%, <italic>p</italic> &lt; 0.001), higher steroid dosages (53.9 vs. 34.2%, <italic>p</italic> = 0.002), renal replacement therapy (37.2 vs. 13.6%, <italic>p</italic> &lt; 0.001), and invasive mechanical ventilation (57.7 vs. 35.8%, <italic>p</italic> &lt; 0.001). In multivariate analysis incorporating hazard ratios (HRs) and confidence intervals (CIs), thrombocytopenia (HR 1.98, 95% CI 1.16–3.37, <italic>p</italic> = 0.012), vasopressor use (HR 3.57, 95% CI 1.80–7.06, <italic>p</italic> &lt; 0.001), and methylprednisolone use at a daily dose ≥ 40 mg (HR 1.69, 95% CI 1.02–2.79, <italic>p</italic> = 1.02–2.79) before CAPA diagnosis were independently associated with CAPA. Patients with CAPA had longer median ICU stays (17 days vs. 12 days, <italic>p</italic> = 0.007), and higher 180-day mortality (65.4 vs. 33.5%, <italic>p</italic> &lt; 0.001) than those without CAPA.</p><p><bold>Conclusions:</bold> Thrombocytopenia, vasopressor use, and corticosteroid treatment were significantly associated with increased risk of incident IPA in COVID-19 patients admitted to ICUs. The occurrence of CAPA may increase the likelihood of long-term COVID-19 mortality.</p>